Abeona Therapeutics Inc.
ABEOHealthcare|Biotechnology|US
$4.17
+0.26 (+6.65%)
DCF Value
$1.00
Tangible Book / Share
$2.24
Cash / Share
$2.57
Clinical Trials (13)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05725018 A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients | Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | P3 | Active | 12 | Open-label | EB-101 Surgical application of RDEB wounds |
| NCT02716246 Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH | MPS IIIA, Sanfilippo Syndrome | P2P3 | Recruiting | 36 | Open-label | UX111, Prophylactic Immunomodulatory (IM) Therapy, Optimized Prophylactic IM Therapy, Adjuvant IM Therapy |
| NCT07700966 A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting | Recessive Dystrophic Epidermolysis Bullosa | Recruiting | 250 | — | — | |
| NCT07717736 Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds | Epidermolysis Bullosa (EB), Recessive Dystrophic Epidermolysis Bullosa (RDEB) | P4 | Not Yet Recruiting | 100 | Open-label | Non-conforming pz-cel surgical application to RDEB wounds, Pz-cel surgical application to DEB wounds |
| NCT00563394 MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers | Diabetic Foot Ulcers | P3 | Completed | 584 | RCT, Double-blind | ofloxacin, MSI-78 |
| NCT04227106 Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) | Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | P3 | Completed | 11 | Open-label | EB-101 |
| NCT00563433 MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers | Diabetic Foot Ulcers | P3 | Completed | 342 | RCT, Double-blind | ofloxacin, MSI-78 |
| NCT03315182 Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB | Mucopolysaccharidosis Type 3 B | P1P2 | Terminated | 11 | Open-label | rAAV9.CMV.hNAGLU |
| NCT01263379 Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa | Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa | P1P2 | Completed | 12 | Open-label | LZRSE-Col7A1 Engineered Autologous Epidermal Sheets |
| NCT04088734 Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease | MPS IIIA, Sanfilippo Syndrome | P1P2 | Terminated | 5 | Open-label | ABO-102 |
| NCT00385502 A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail | Onychomycosis | P2 | Completed | 40 | Open-label | EcoNail™ (econazole 5%/SEPA® 18% nail lacquer) |
| NCT05708677 A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB | RDEB | By Invite | 22 | — | EB-101 | |
| NCT04655911 A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101 | Mucopolysaccharidosis III-B | Terminated | 1 | — | ABO-101 |